CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
Status:
Terminated
Trial end date:
2018-11-26
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies 6, 8-bis (benzylthio) octanoic acid (CPI-613) in treating
patients with myelodysplastic syndromes who failed previous therapy. Sometimes when
chemotherapy or biological therapy is given, it does not stop the growth of tumor cells. The
tumor is said to be resistant to treatment. 6, 8-bis (benzylthio) octanoic acid may interfere
with the growth of tumor cells and may be an effective treatment for myelodysplastic
syndromes that did not respond to previous therapy.